Navigation Links
Mesa Labs Reports 8% Increase in Second Quarter Revenues
Date:11/5/2013

LAKEWOOD, Colo., Nov. 5, 2013 /PRNewswire/ -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, "Mesa" or the "Company") today reported an eight percent increase in revenues for the second quarter ended September 30, 2013.

Revenues for the second quarter increased eight percent to $12,676,000 as compared to $11,706,000 for the same quarter last year.  Net income for the second quarter decreased 14 percent to $1,932,000 or $0.54 per diluted share of common stock as compared to $2,248,000 or $0.64 per diluted share of common stock for the same quarter last year.  Net income for the second quarter was impacted by a net $638,000 (before tax) of unusual items, comprised of a $1,106,000 expense for uncollected sales tax liabilities which was partially offset by a gain of $468,000 related to the sale of the Nusonics product line.  The net impact of these unusual items (after tax) reduced our net income per diluted share of common stock by $0.12 for the second quarter.

Revenues for the six months ended September 30, 2013 increased seven percent to $23,894,000 as compared to $22,266,000 for the same period last year.  Net income for the six months ended September 30, 2013 decreased 13 percent to $3,792,000 or $1.06 per diluted share of common stock as compared to $4,348,000 or $1.23 per diluted share of common stock for the same period last year.  Net income for the six months ended was impacted by the same second quarter unusual items noted above.  The net impact of these unusual items (after tax) reduced our net income per diluted share of common stock by $0.11 for the six months ended September 30, 2013.

On a non-GAAP basis, adjusted net income (which excludes the non-cash impact of amortization of intangible assets, net of tax) for the second quarter decreased 13 percent to $2,337,0001 or $0.65 per diluted share of common stock as compared to $2,684,000 or $0.76 per diluted share of common stock for the same quarter last year.  Adjusted net income for the six months ended September 30, 2013 decreased 11 percent to $4,574,000 or $1.28 per diluted share of common stock as compared to $5,167,000 or $1.46 per diluted share of common stock for the same period last year.  Adjusted net income for the second quarter and the six months ended September 30, 2013 was impacted by the same second quarter unusual items noted above.

"Mesa experienced solid revenue growth during the first six months of fiscal year 2014", commented John J. Sullivan, President and CEO.  "Organic growth in our Biological Indicators ("BI") division of four percent was complemented by 10 percent growth in our Instruments division, driven primarily by the Bios and SureTorque acquisitions, partially offset by the divestiture of our Nusonics line of instruments.  Additionally gross profit increased by five percent for the six month period, however gross profit margin percentage for the same period decreased by two percentage points.  This was due primarily to a BI product replacement initiative in the first quarter and the application of purchase accounting on assets associated with the SureTorque acquisition in the second quarter.  We expect our gross profit margin percentage to recover to normal levels during the second half of the fiscal year."

"Mesa's operating income decreased by $973,000 and $1,150,000 for the second quarter and the six months ended September 30, 2013, respectively as compared to the same periods last year", continued John Sullivan.  "The decrease was primarily due to the $1,106,000 (before tax) expense associated with uncollected sales tax liabilities associated with prior periods.  This expense was accrued for in the second quarter, although the actual cash outlay will likely be spread out over several quarters (if not years) into the future.  It is however important to note that without this unusual expense, operating income would have been relatively flat for both the second quarter and six month period.  We believe that the unusual sales tax expense is behind us and as a result, we expect Mesa's profitability to return to normal levels in the second half of the fiscal year."

1 The non-GAAP measures of adjusted net income and adjusted net income per diluted share are defined to exclude the non-cash impact of amortization of intangible assets, net of tax. A reconciliation between these non-GAAP measures and their GAAP counterparts is set forth in the table below, along with additional information regarding their use.

Financial SummaryStatements of Income

(Unaudited)(Amounts in thousands, except per share data)Three months ended
September 30,Six months ended
September 30,2013201220132012Revenues

$ 12,676

$ 11,706

$ 23,894

$ 22,266Cost of revenues

5,076

4,458

9,497

8,562  Gross profit

7,600

7,248

14,397

13,704Operating expenses

5,085

3,760

8,839

6,996  Operating income

2,515

3,488

5,558

6,708Other income (expense), net

423

(36)

395

(70)  Earnings before income taxes

2,938

3,452

5,953

6,638Income taxes

1,006

1,204

2,161

2,290  Net income

$  1,932

$   2,248

$  3,792

$  4,348Net income per share (basic)

$ 0.57

$ 0.67

$ 1.11

$ 1.30Net income per share (diluted)

0.54

0.64

1.06

1.23Weighted average common shares outstanding:Basic

3,412

3,349

3,403

3,343Diluted

3,592

3,538

3,568

3,531 Balance Sheets(Amounts in thousands)September 30, 
2013
(Unaudited)March 31,
2013Cash and cash equivalents

$   3,424

$   4,006Other current assets

15,177

15,449  Total current assets

18,601

19,455Property, plant and equipment, net

7,772

7,406Other assets

39,414

39,058  Total assets

$ 65,787

$ 65,919Liabilities

$   9,215

$ 13,166Stockholders' equity

56,572

52,753  Total liabilities and stockholders' equity

$ 65,787

$ 65,919 Reconciliation of Non-GAAP Measures(Unaudited)(Amounts in thousands, except per share data)Three months ended
September 30,Six months ended
September 30,2013201220132012Net income

$ 1,932

$ 2,248

$   3,792

$ 4,348Amortization of intangible

  assets, net of tax

 

405

 

436

 

782

 

819Adjusted net income

$ 2,337

$ 2,684

$   4,574

$ 5,167Adjusted net income per share (basic)

$ 0.68

$ 0.80

$ 1.34

$ 1.55Adjusted net income per share (diluted)

0.65

0.76

1.28

1.46Weighted average common shares outstanding:Basic

3,412

3,349

3,403

3,343Diluted

3,592

3,538

3,568

3,531The non-GAAP measures of adjusted net income and adjusted net income per share presented in the reconciliation above are defined to exclude the non-cash impact of amortization of intangible assets, net of tax. The tax effect is calculated using the average corporate rate for that period multiplied by the amortization. We believe that excluding these acquisition related expenses provides the ability to understand the benefits of acquisitions based on their cash return.

We provide non-GAAP adjusted net income and non-GAAP adjusted net income per share amounts in order to provide meaningful supplemental information regarding our operational performance. Our management uses non-GAAP measures to evaluate the performance of our business and to compensate employees. This information facilitates management's internal comparisons to our historical operating results as well as to the operating results of our competitors. Since management finds this measure to be useful, we believe that our investors can benefit by evaluating both non-GAAP and GAAP results.

Our management recognizes that items such as amortization of intangible assets can have a material impact on our net income. To gain a complete picture of all effects on our profit and loss from any and all events, management does (and investors should) rely upon the GAAP statements of income. The non-GAAP numbers focus instead upon our core operating business.

Readers are reminded that non-GAAP measures are merely a supplement to, and not a replacement for, or superior to financial measures prepared according to GAAP. They should be evaluated in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

About Mesa Laboratories, Inc.

We pursue a strategy of focusing primarily on quality control products, which are sold into niche markets that are driven by regulatory requirements. We prefer markets that have limited competition where we can establish a commanding presence and achieve high gross margins.  We are organized into two divisions across four physical locations.  Our Instruments Division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, semiconductor and petrochemical industries.  Our Biological Indicators Division manufactures and markets biological indicators and distributes chemical indicators used to assess the effectiveness of sterilization processes, including steam, gas, hydrogen peroxide and radiation, in the hospital, dental, medical device and pharmaceutical industries.

Forward Looking Statements

This press release may contain information that constitutes "forward-looking statements." Generally, the words "believe," "expect," "intend," "estimate," "anticipate," "project," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to revenue growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. These risks and uncertainties include, but are not limited to, those described in our Annual Report on Form 10-K for the year ended March 31, 2013, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Mesa Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. Luminex Corporation Reports First Quarter 2012 Results
9. Hospira Reports First-Quarter 2012 Results
10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
11. The Female Health Company Reports Second Quarter Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
Breaking Medicine News(10 mins):